Search
Jon Norris shares highlights from the 2024 HSBC Venture Healthcare Full-Year Report
He provides a 2024 year-end recap and 2025 outlook DOWNLOAD THE FULL REPORT #Sponsored
Jan 10, 2025
Baird biotech analyst Jack Allen recaps ASH and other recent news, and shares his outlook for top names in 2025
Jack Allen discusses data that Arcellx and Vor had at last week's ASH annual meeting, and discusses Mereo, Ultragenyx, Instil Bio, Taysha...
Dec 18, 2024
Dimension's Zavain Dar talks about raising a $500M second fund, and describes the firm's ethos of investing in companies that are highly focused in both life sciences and technology
He discusses the founding of Dimension, and highlights entrepreneurs and portfolio companies that have matched the firm's focused...
Dec 16, 2024
NewYorkBIO CEO Jennifer Hawks Bland discusses their annual event at the New York Stock Exchange and what is on the mind of companies today
Over 600 people registered for the event and took in company presentations and networking on the floor of the NYSE.
Dec 10, 2024
ApexOnco's Jacob Plieth shares his take on what to watch for at the 2024 ASH Annual Meeting
He talks modalities and targets, and comments on Arcellx, Galapagos, BeiGene, Nurix, Kura, JNJ, Syndax, AbbVie AstraZeneca, CellCentric,...
Dec 7, 2024
London Healthcare Week: Forbion Managing Partner Sander Slootweg shares his thoughts on the year ahead, the IPO market, M&A environment, areas of interest, and more
Fresh off of raising more than €2 billion for two new funds in October, he gives his take on the biotech markets both in Europe and...
Nov 20, 2024
From Seoul: Kicking off BiotechTV's one week visit to Korea by getting an overview of the growth and current state of biotech in the country from KoreaBIO
KoreaBIO Vice President Seung-Kyou Lee and Director of International & Public Affairs Jurie Hwang describe the enormous growth the sector...
Nov 20, 2024
SITC 2024: Parker Institute for Cancer Immunotherapy CSO John Connolly gives an overview of the latest advances in IO
He discusses the latest in TILs, cell therapy, multispecifics, oncolytic viruses and more.
Nov 9, 2024
BioHouston CEO Ann Tanabe kicks off the 2024 Texas Life Science Forum
From the largest conference for life sciences in Texas each year, she describes the significant growth in infrastructure, startups,...
Nov 7, 2024
BIO-Europe: Pareto Securities' Biotech Analyst Dan Akschuti shares his thoughts on the conference and discusses recent company successes in the nordic region
He says there has been an upswing in investors looking at companies. Plus, his thoughts on BioInvent, Oculis, and Camurus. Brought to you by
Nov 5, 2024
BIO-Europe: Karolinska Institutet professor and physician Anna Wedell discusses the work she is doing and what areas of research excite her today
She discusses building systems around early diagnostics and treatment, rare disease discovery, mitochondrial disease and the brain,...
Nov 5, 2024
BIO-Europe: The CEO of Flerie, a publicly traded life sciences investment firm, discuses the firm's investment strategy and the health of biotech in the region
Ted Fjällman covers the history of the firm, and rationale for going public this year. Plus, he highlights portfolio companies such as...
Nov 4, 2024
The CEO of the nonprofit MassChallenge describes the way it supports startups and entrepreneurs, and why it has chosen Dallas as its second region of major focus in the U.S. outside of Boston
Cait Brumme highlights MassChallenge's equity-free model and how it helps biotech entrepreneurs from the earliest stages to understanding...
Oct 30, 2024
Biotech entrepreneur RA Session II describes converting science from UT Southwestern into companies - he currently has a new one that is in stealth mode
Having been involved with Reata, Taysha Gene Therapies (founder), ReCode Therapeutics and more, RA has a good handle on the biotech scene...
Oct 29, 2024
The CEO of LH Capital, a key supporter of the life sciences industry in North Texas, describes the progress the biotech community here has made over the last year
Nicole Small discusses events that have recently taken place like the acquisition of Reata, ARPA-H choosing Dallas for a regional center,...
Oct 29, 2024
UT Southwestern professor Philipp Scherer talks about his work focusing on adipose cells and a local biotech company, PriveBio, that has come out of it
Dr. Scherer describes the work he is doing in areas like diabetes and fibro-inflammation. Plus, PriveBio's programs focusing on...
Oct 29, 2024
Piper Sandler analyst Biren Amin discusses recent news in ATTR cardiomyopathy, ophthalmology, Duchenne muscular dystrophy, and more
Biren Amin joins BiotechTV from the NYSE and discusses BridgeBio, Ocular Therapeutix, Apellis, Sarepta, Solid Bio, Cargo Therapeutics,...
Oct 22, 2024
Backed by a conglomerate that has pharma expertise, Rome based Angelini Ventures has a $300M fund that invests broadly in life sciences and healthcare
Medical Director Fabrizio Calisti describes the fund, its foundation in the CNS but broad interest today, current portfolio holdings, and...
Oct 18, 2024
The Foundation for Innovation and Tech Transfer has consolidated business development and tech transfer for 7 institutions in northern Italy to expedite the commercialization of the area's research
Managing Director Marco Baccanti explains how the foundation was created last year to boost the amount of IP and licensing that is...
Oct 16, 2024
The co-founder of the startup Ousia Pharma describes working from Copenhagen's BioInnovation Institute on his company's next-generation enhancer to GLPs
Anders Bue Klein describes how the BI has made it easier for founders like him to take work from university and turn it into a company....
Oct 10, 2024
.png){kind=logo}
